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ABSTRACT: Cold atmospheric plasma (CAP) is produced by ionizing a chosen gas, thereby 
creating charged and reactive species. The reactive species generated are capable of inducing a 
range of biomedically relevant interactions including blood coagulation. However, the underlying 
biochemical processes of plasma-assisted blood coagulation are largely unknown,  and data quan-
tifying blood clot formation or the impact of system parameters on the intensity of the blood clot 
are scarce. In this study, blood coagulation was quantified by measuring hemoglobin absorbance. 
System parameters of the kINPen plasma jet were investigated and compared, including treatment 
time, distance from the plasma source and gas flow rate. These investigations were combined with 
optical emission spectroscopy to associate the species generated in the plasma effluent with the 
effect on coagulation efficiency. In this study, we have proposed a method to quantitatively assess 
plasma-induced blood coagulation to directly compare the clotting capabilities of other plasma 
systems and to explicate the mechanism of plasma-assisted blood coagulation. 
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I. INTRODUCTION
Cold atmospheric plasma (CAP) is an ionized gas that can be generated using different 
gases or gas mixtures, which consists of free electrons, radicals, and positively and neg-
atively charged particles.1 The antimicrobial effects of CAP are well studied and have 
been proven to inactivate bacteria2,3 and fungi,4 and to have similarly cytotoxic effects 
on cancer cells.5 A range of CAPs have also been investigated for biomedical application 
in terms of wound healing and disinfection6,7 and have been proven to rapidly coagulate 
blood.8–12
Coagulation is the formation of a blood clot and occurs when blood changes from 
a liquid to a solid. Coagulation is an important primary step of hemostasis and occurs 
immediately after damage to the endothelium of the blood vessel to prevent blood loss 
from the injured vessel and to seal the area from infection.13 Disruption of the endotheli-
um activates platelets, causing them to adhere to the subendothelium, forming a plug.14 
Simultaneously, secondary hemostasis is triggered; this is a complex cascade involving 
protein coagulation factors in the blood plasma culminating in the formation of fibrin 
strands forming a mesh to reinforce the platelet plug.15 The coagulation cascade requires 
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calcium ions as a cofactor; coagulation factors use the ions to bind to the negatively 
charged phospholipid surface of platelets.16 Anticoagulants work by chelating calcium 
ions, causing conformational changes in the coagulation factors, which prevents activa-
tion of the coagulation cascade. 
The release of chemokines from the clot and surrounding tissues stimulates leukocyte 
migration to the area to prevent infection and promote wound healing.17 Coagulation is 
highly conserved in vertebrates and involves both cellular (platelet) and protein (coagula-
tion factor) components.16
Plasma-coagulation devices, such as the argon plasma coagulator (APC), are used in 
clinical medicine to ensure rapid coagulation.18,19 The APC is a high-frequency monop-
olar instrument used for thermal coagulation through cauterization and desiccation of 
the blood.20 CAP would be ideal for bleeding control to stimulate the natural coagulation 
cascade with little damage to surrounding tissues. It has been previously demonstrat-
ed that anticoagulated blood samples can be clotted by CAP produced by a dielectric 
barrier discharge11 and plasma torches.21 There are multiple theories on the biochem-
ical mechanisms of plasma-induced blood coagulation, such as activation of erythro-
cyte-platelet interactions and the coagulation cascade by reactive oxygen species (ROS) 
generated by CAP.11 Some studies have shown that platelet function and aggregation 
are influenced by oxygen species.22,23 There is also evidence to suggest that CAP has a 
direct effect on blood proteins, causing coagulation with no change to Ca2+ concentration 
or pH of the sample.11 Different studies have employed a range of plasma-generating 
systems and inducer gases. Thus, CAP has been shown to induce blood coagulation, but 
the underlying biochemical mechanisms and influence of process parameters remain 
poorly understood. Using a method based on specific absorbance of hemoglobin at 405 
nm, we analyzed plasma-induced blood coagulation in a quantitative manner and to 
relate clotting efficiency to different system parameters. In this study, we compared the 
intensity of blood clot formation in relation to different cold plasma jet process param-
eters by measuring hemoglobin absorbance as the biological response. We also utilized 
spectroscopic diagnostics of generated reactive species at the selected parameters and 
correlated them to the quantified blood clot to begin to elucidate the biochemical mech-
anisms of plasma-induced blood clot formation. 
II. MATERIALS AND METHODS
A. Plasma System 
The atmospheric plasma pressure jet (APPJ) kINPen Plasma MED (INP Greifswald/
neoplas tools GmbH Greifswald, Germany) was used for these investigations. This de-
vice is CE-certified as a medical device, meeting EU safety, health, and environmental 
regulations.24,25 The apparatus consists of a hand-held unit, a DC power supply, and a gas 
supply unit. Plasma is generated in the pen and extends to the surrounding air outside the 
nozzle, and the discharge effluent is directed toward the sample.
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The handheld unit was mounted on a platform that controlled the vertical and hor-
izontal movement of the jet to within 0.01 mm. Argon gas was employed as a working 
gas as a noble, normally unreactive stable gas.24 For blood coagulation studies, process 
parameters studied using the kINPen jet included time, distance, and gas flow rate.
B. Blood Collection and Preparation of Blood Components
Anticoagulated blood samples were collected from the bovine coccygeal vein, under 
veterinarian supervision using sterile tubes containing anticoagulants EDTA or sodium 
citrate (BD Vacutainer®) and was appropriately inverted according to supplier guide-
lines to ensure that the anticoagulant was correctly mixed throughout the sample. Sam-
ples were stored at 4°C and processed within 12 hours of collection. The blood collec-
tion tubes were designed with maximum and minimum fill lines to draw the appropriate 
volume of blood to ensure a correct blood-to-additive ratio.
C. Plasma-Induced Blood Clotting
The plasma-induced blood clotting experiments were carried out in 96-well microtiter plates 
with 50-µl blood samples undergoing plasma treatment. The negative control was a 50-µl 
blood sample left in air for the same period of time. The positive control was 50 µl blood 
treated with plasma for 10 minutes for a complete clot to be achieved with no liquid fraction. 
D. Quantification of Plasma-Induced Blood Clot
Quantification of blood coagulation was achieved by adapting the Harboe spectropho-
tometric assay for the measurement of hemoglobin, using absorbance measurement at 
405 nm26 in a microtiter plate reader. The treated blood sample was washed with PBS 
(Sigma-Aldrich, Dublin, Ireland), and the unclotted blood portion was separated from 
the formed blood clot by pipetting it into an Eppendorf tube and acidifying the solution to 
achieve a 3% acetic acid solution (Sigma-Aldrich, Dublin, Ireland). The remaining blood 
clot was separately dissolved using 3% acetic acid in PBS, and the well was washed three 
times with 3% acetic acid to remove any residual hemoglobin, then it was transferred 
to a separate Eppendorf tube. Both the unclotted fraction and dissolved blood clot were 
appropriately diluted, and absorbance readings were recorded using a Synergy HT micro-
plate reader (Biotek, Potton, UK). These results were compared to an untreated whole-
blood sample as well as a control blood clot, respectively, to determine a blood clotting 
index (BCI) as described in Eq.1, similar to that described by Wang.27
BCI (%) =                              Absorbance of acidified blood                       X 100
                        Absorbance of acidified whole blood/control clotted blood                  (1)
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E. Optical Emission Spectroscopy
Optical emission spectroscopy (OES) was recorded using an optical fiber spectrometer 
(Edmund Optics, York, UK) in the ultraviolet (UV), visible (VIS), and near-infrared 
(NIR) regions, including the emission of OH radicals at 309 nm and the excited argon 
species at 750 nm and 811 nm. The plasma images were taken along the plasma plume 
while treating the sample, with spatial resolution of 0.01 mm. The spectrometer was 
calibrated against a halogen lamp. 
III. RESULTS 
CAP has been shown to induce blood coagulation, but the underlying biochemical mech-
anisms and influence of plasma parameters remain poorly understood. Using a method 
based on the specific absorbance of hemoglobin at 405 nm, we analyzed plasma-induced 
blood coagulation in a quantitative manner and attempted to relate clotting efficiency to 
different system parameters. 
The system parameters applied included treatment time, distance from the plasma 
source, and gas flow rate. These factors were found to effect blood clot formation and 
were correlated to OES data to elucidate the influence of plasma on the coagulation 
cascade. 
A. Treatment Time
The optical emission spectra of the argon plasma discharged in air (Fig. 1a) shows 
that the overall emission intensity, an indication of the energy in the plasma system, 
stabilized over time. The individual spectra of the wavelengths of interest, namely 
excited argon at 750 nm and 811 nm and the hydroxyl radical (OH) emission at 309 
nm, also showed stabilization over the treatment time (Fig. 1b). The ratio of the spec-
tral lines recorded for the excited argon species is proportional to the electron energy 
distribution factor (EEDF) and is a mean value of electron energy.28 The intensity of 
the plasma was demonstrated to stabilize over time using OES, and treatment times in 
excess of 2 min were used for more reproducible results. The intensity of OH emission 
at 309 nm was higher than the argon emission. Optical emission spectra were recorded 
2 mm above the sample, with the jet at a distance of 18 mm from the sample and a gas 
flow rate of 2.5 cm3/s. The percentage of CAP-clotted blood increased with treatment 
time (Fig. 2). 
When taking the OES spectra over treatment time and comparing them to the effect 
of distance from the plasma jet on the plasma intensity (Fig. 3), we observed interactive 
effects. Although there was an increase in plasma-induced blood clotting in conjunction 
with treatment time and the plasma intensity was stable, the intensity of the plasma 
reaching the sample decreased with increasing distance. 
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C. Distance from the Sample
As the plasma jet distance from the blood sample was increased at a fixed treatment 
time of 4 minutes and gas flow rate of 2.5cm3/s, there was a marked reduction in plas-
ma-induced clotting. Blood clotting decreased linearly with an increase in distance from 
the plasma source, as shown in Fig. 4(a), and the captured emission spectra of the reac-
tive species reaching the sample also indicated overall decrease with distance (Fig. 4b). 
These data suggest a relationship between blood coagulation and short-lived reactive 
species in the plume, which are dispersed, resulting in a decrease in the intensity of the 
plume reaching the sample (Fig. 4c).
FIG. 1 (a): Overall intensity recorded with OES diagnostics of the argon plasma jet over time; 
(b): Intensity recorded at 309 nm, 750 nm, and 811 nm, respectively
FIG. 2: The effect of time on clot formation in anticoagulated blood treated with the plasma jet
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D. Gas Flow Rate
The intensity of the plasma plume stabilized with increasing gas flow rate after an initial 
increase (Fig. 5a). No reactive species were generated with a gas flow rate <1.5 cm3/s. This 
stability in emission led to treatment at a gas flow rate of 2.5cm3/s. With a gas flow rate 
>3.5cm3/s, there was visible dispersion of the sample due to the gas pressure. Emission 
spectra of the hydroxyl radical at 309 nm should have offered a similar pattern; however, 
we observed a decrease in the hydroxyl radical reaching the sample (Fig. 5b), due to a pos-
sible quenching of species by the sample and resulting increase of the blood clot (Fig. 5c). 
Therefore, the ideal gas flow rate and treatment time are shown in Fig. 6. The highest plasma 
intensity coincides with a gas flow rate of 1.9–2.4cm3/s and a treatment time of 4 minutes.
IV. DISCUSSION
Cold plasmas have been investigated for decades, but research into their use as selective 
therapeutic instruments is relatively recent. Employment of surgical plasma technology 
is already in operation with the APC based on ablation and dessication. An alternative 
therapy, which could rapidly coagulate during surgery or upon injury and offer little to 
no collateral damage, would be of great importance to the medical field. Different CAP 
systems, including the air plasma torch12,21 and floating-electrode dielectric barrier dis-
charge,9,10,29 have proven to rapidly coagulate blood in vitro and in vivo with no effect 
to the surrounding tissues.9,29–37 A method of comparison between systems is needed to 
assess different treatment parameters such as time and distance from the plasma source. 
In the present study, we demonstrated a method for comparing the clotting capabilities 
of different CAP systems. In previous studies, the blood clotting ability of CAP has only 
been assessed qualitatively using visual evaluation.8,10,11
FIG. 3: The effect of treatment time and distance on overall plasma intensity 
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FIG. 4: The effect of distance from plasma source (a) on blood clot formation; (b) the effect of 
distance on the intensity of plasma plume; (c) the combined effect of gas flow rate and distance 
on plasma intensity
FIG. 5: The effect of gas flow rate on (a) intensity of the argon plasma; (b) emission spectra of 
the hydroxyl radical at 309 nm; (c) blood clot formation
FIG. 6: The effect of treatment time and gas flow rate on the intensity of the plasma jet
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Quantitative assessment of blood coagulation using an argon plasma jet was con-
ducted to compare clotting efficiency to the system parameters of distance from plas-
ma source, gas flow rate, and treatment time. The plasma was characterized using 
optical emission spectroscopy. Our results suggest an important role for short-lived 
oxygen plasma species, such as the hydroxyl radical, in initiating blood coagulation. 
Reactive oxygen species, such as hydrogen peroxide and hydroxyl radical,38,39 have 
been implicated in influencing the coagulation cascade via the activation of plate-
lets.40,41 It has been suggested that ROS cause clotting by inactivating anticoagula-
tion agents that control clotting, such as endothelial-derived relaxing factor (EDRF), 
which counteracts platelet aggregation in vivo.40 However, treatment time and gas 
flow rate also effect blood coagulation but they ultimately plateau, pointing to opti-
mal parameter selection for coagulation. The diminution in blood-clot formation with 
increasing distance between the plasma plume and the blood sample was attributed to 
the reduction of reactive species transmitted to the sample. Integrating these results 
with the quantitative assessment of blood clot formation, we were able to optimize 
the distance from the sample in conjunction with treatment time and the gas flow rate 
applied to the device.
The blood samples used in this experiment included two different types of anticoag-
ulants that sequester calcium ions in the blood, thus preventing their involvement in the 
coagulation cascade and use by coagulation factors in binding to phospholipid surfac-
es.16 Sodium citrate chelates the calcium ions in blood, but this process can be reversed 
through the addition of calcium ions to the sample. EDTA irreversibly binds the calcium 
ions in blood and prevents their influence in the coagulation cascade, thereby preventing 
the blood from forming clots. Our results revealed a tendency of the EDTA blood to 
exhibit better clot formation under CAP treatment. The clotting of anticoagulated blood, 
and of EDTA-treated blood in particular, with CAP suggests that plasma-assisted coag-
ulation is not dependent on Ca2+ ions. These findings are similar to those of Kalghatgi 
et al.11
V. CONCLUSIONS
The ability of CAP to rapidly coagulate anticoagulated blood in a matter of minutes 
indicates the importance of this tool in a medical scenario to prevent hemorrhaging and 
to seal a wound from infection. 
The biochemical mechanisms whereby the coagulation cascade is activated by 
CAP remain to be elucidated, but the methods employed here can be used not only 
to compare coagulation capabilities associated with different process parameters but 
also to directly quantitatively compare coagulation capabilities across different sys-
tems to explain and optimize the cascade activation mechanism. These results also 
point to the enhanced role of some short-lived reactive species, suggesting an oppor-
tunity to maximize coagulative effects through varying process parameters such as 
inducer gas. 
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